Jacqui Thompson
6 Papers
3 Citations
Jacqui Thompson is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 2, co-authored 2 publications.
Chat about Author
Papers
Granulocyte colony-stimulating factor and autologous CD133-positive stem-cell therapy in liver cirrhosis (REALISTIC): an open-label, randomised, controlled phase 2 trial
Philip N. Newsome,Philip N. Newsome,Richard Fox,Richard Fox,Andrew King,Andrew King,Darren Barton,Darren Barton,Nwe-Ni Than,Nwe-Ni Than,Joanna Moore,Chris Corbett,Sarah Townsend,James Thomas,Kathy Guo,Kathy Guo,Diana Hull,Diana Hull,Heather A Beard,Jacqui Thompson,Anne P.M. Atkinson,Carol Bienek,Neil W. A. McGowan,Neil Guha,John D.M. Campbell,Dan Hollyman,Deborah Stocken,Christina Yap,Stuart J. Forbes +28 more
TL;DR: G-CSF with or without haemopoietic stem-cell infusion did not improve liver dysfunction or fibrosis and might be associated with increased frequency of adverse events compared with standard care.
143
Liver homing of clinical grade Tregs after therapeutic infusion in patients with autoimmune hepatitis.
Ye Htun Oo,Ye Htun Oo,Susan Ackrill,Richard Cole,Lee Jenkins,Philip Anderson,Hannah C. Jeffery,Nicholas Jones,Louisa E. Jeffery,Philipp Lutz,Rebecca E. Wawman,Amrita Kaur Athwal,Jacqui Thompson,Joanna Gray,Kathy Guo,Darren Barton,Gideon M. Hirschfield,Timothy Wong,Peter Guest,David H. Adams,David H. Adams +20 more
- 21 Aug 2019
TL;DR: The novel findings suggest that the liver is a good target organ for Treg cellular therapy, supporting the development of clinical trials to test efficacy in autoimmune hepatitis and other autoimmune liver diseases.
Repair of acute respiratory distress syndrome by stromal cell administration (REALIST): a structured study protocol for an open-label dose-escalation phase 1 trial followed by a randomised, triple-blind, allocation concealed, placebo-controlled phase 2 trial
Ellen Gorman,Manu Shankar-Hari,Phillip A Hopkins,William Tunnicliffe,Gavin D. Perkins,Jonathan A Silversides,Peter J. McGuigan,Colette Jackson,Roisin Boyle,Jamie McFerran,Cliona McDowell,Christina Campbell,Margaret McFarland,Jon Smythe,Jacqui Thompson,Barry Williams,Gerard F. Curley,John G. Laffey,Mike Clarke,Daniel F. McAuley,Cecilia O'Kane +20 more
TL;DR: In this article , a CD362 enriched MSC product (REALIST ORBCEL-C) was used in patients with moderate to severe ARDS due to COVID-19 and other causes.
Repair of Acute Respiratory Distress Syndrome in COVID-19 by Stromal Cells (REALIST-COVID Trial): A Multicentre, Randomised, Controlled Trial.
Ellen Gorman,Jennifer Rynne,Hannah Gardiner,Anthony J. Rostron,Jonathan Bannard-Smith,Andrew Bentley,David Brealey,Christina Campbell,Gerard F. Curley,Mike Clarke,Ahilanadan Dushianthan,Philip Hopkins,Colette Jackson,K. Kefela,Anna Krasnodembskaya,John G. Laffey,Cliona McDowell,Margaret McFarland,Jamie McFerran,Peter J. McGuigan,Gavin D. Perkins,Jonathan A Silversides,Jon Smythe,Jacqui Thompson,William Tunnicliffe,Ingeborg D Welters,Laura Amado-Rodríguez,Guillermo M. Albaiceta,Barry Williams,Manu Shankar-Hari,Daniel F. McAuley,Cecilia O'Kane +31 more
TL;DR: In this article , the authors investigated safety and efficacy of ORBCEL-C (CD362-enriched, umbilical cord-derived MSCs) in COVID-related acute respiratory distress syndrome (ARDS).
3
S44 Repair of acute respiratory distress syndrome in COVID-19 by stromal cells (REALIST-COVID trial): 1 year follow up for safety and pulmonary dysfunction
HJ Gardiner,Ea Gorman,AJ Rostron,Manu Shankar-Hari,Jonathan Bannard-Smith,A. Bentley,David Brealey,Christina Campbell,Gerard F. Curley,Mike Clarke,A Dushianthan,Phillip A Hopkins,Colette Jackson,K. Kefela,J. Laffey,Cliona McDowell,Margaret McFarland,Jamie McFerran,Peter J. McGuigan,G Perkins,Jonathan A Silversides,J. Smythe,Jacqui Thompson,WS Tunnicliffe,I Welters,Barry Williams,D. McAuley,C. O’Kane +27 more
- 01 Nov 2022
TL;DR: In this article , the safety of ORBCEL-C MSCs in patients with moderate to severe ARDS due to COVID-19 was investigated at 1 year follow up.